Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.85 |
| ▸ | IL1B | P01584 | 4/20 | 0.61 |
| ▸ | GZMB | P10144 | 1/20 | 0.57 |
| ▸ | ELANE | P08246 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12914457 | 1.00 | CASP1 (0.85) | CASP1IL1BGZMBELANEPOLB | |
| SCHEMBL12914539 | 0.92 | CASP1 (1.00) | CASP1IL1BGZMBELANEPOLB | |
| SCHEMBL4454203 | 0.92 | CASP1 (1.00) | CASP1IL1BGZMBELANEPOLB | |
| SCHEMBL12450460 | 0.83 | CASP1 (0.88) | CASP1IL1BGZMBELANEPOLB | |
| SCHEMBL12450464 | 0.82 | CASP1 (0.86) | CASP1IL1BELANEPOLBKDM4E | |
| SCHEMBL949229 | 0.79 | CASP1 (0.69) | CASP1IL1BPOLBKDM4EALDH1A1 | |
| SCHEMBL12450650 | 0.79 | CASP1 (0.67) | CASP1IL1BPOLBKDM4EALDH1A1 | |
| SCHEMBL27476686 | 0.77 | CASP1 (0.61) | CASP1IL1BPOLBKDM4EALDH1A1 | |
| SCHEMBL5344787 | 0.77 | CASP1 (1.00) | CASP1IL1BGZMBELANE | |
| SCHEMBL9011667 | 0.76 | ELANE (0.77) | CASP1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | CASP1 5/4885IL1B 1/4885GZMB 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.